Dioun S, Chen L, De Meritens AB, St Clair CM, et al. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy. Gynecol Oncol 2024;182:70-74.
PMID: 38262241